elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Fingolimod
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Fingolimod
RIS
0.000
(Research Intensity Score)
Papers
78
Top papers
Diagnosis and Treatment of Multiple Sclerosis
2021 · 1179 citations
Macrophage‐Disguised Manganese Dioxide Nanoparticles for Neuroprotection by Reducing Oxidative Stress and Modulating Inflammatory Microenvironment in Acute Ischemic Stroke
2021 · 318 citations
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
2021 · 314 citations
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
2019 · 573 citations
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study
2025 · 9 citations
Intranasal blood-brain barrier bypass enables sequential mitochondria-targeted bioengineered nanolamellar system for ischemic stroke therapy
2026 · 6 citations
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis
2025 · 8 citations
De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study
2025 · 10 citations
Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis
2022 · 43 citations
Newest papers
Intranasal blood-brain barrier bypass enables sequential mitochondria-targeted bioengineered nanolamellar system for ischemic stroke therapy
2026 · 6 citations
FEATURES OF DEVELOPING THE TEACHING MANUAL FOR THE COURSE “OXIDIZING AGENTS IN PHARMACY: FROM CHEMICAL ANALYSIS TO CLINICAL APPLICATION” FOR FUTURE PHARMACISTS AND BIOTECHNOLOGISTS WITHIN THE ERASMUS+ UKRAINEDIGITRANS PROJECT
2026
Lifestyle Modification Rehabilitation and Pharmacotherapy in Multiple Sclerosis
2026
Mitochondrial bioenergetic remodeling underlies fingolimod-induced immunometabolic adaptation in multiple sclerosis
2026
Fingolimod overcomes cisplatin resistance in esophageal squamous cell carcinoma by targeting NUP54 to disrupt homologous recombination repair
2026
MicroRNA Expression Profiles as Biomarkers of Response to Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review
2026
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study
2025 · 9 citations
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis
2025 · 8 citations
De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study
2025 · 10 citations
Browse all papers →
Fingolimod's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Fingolimod's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link